GLP-1受体激动剂与2型糖尿病患者非动脉炎性前部缺血性视神经病变风险
该队列研究模拟务实目标试验,利用英国临床实践研究数据链比较成人2型糖尿病患者新启用GLP-1受体激动剂与DPP-4抑制剂的NAION发生风险。1年时GLP-1受体激动剂组NAION发生率为18.5/10万,DPP-4抑制剂组为7.2/10万,风险比2.56(95%CI 1.44-4.86),风险差11.3/10万,提示GLP-1受体激动剂与NAION风险升高相关,尤其在年轻、男性、曾吸烟及HbA1c大幅下降者中。
要点
- GLP-1受体激动剂较DPP-4抑制剂1年NAION风险比2.56(95%CI 1.44-4.86)
- 风险差为11.3/10万,绝对风险增加幅度较小
- 风险在前6个月较高,且年轻、男性、曾吸烟及HbA1c降幅≥1%者风险更高
核心结论
- 在成人2型糖尿病患者中,启用GLP-1受体激动剂较DPP-4抑制剂与1年NAION风险升高相关。
研究设计与样本
- 采用活性对照、新用户队列设计模拟务实目标试验,数据来自英国临床实践研究数据链。
- 纳入年龄≥18岁、医生诊断2型糖尿病且新启用GLP-1受体激动剂或DPP-4抑制剂的患者。
- 以DPP-4抑制剂为对照,因其可作二线治疗且与NAION无既定关联;采用倾向评分精细分层加权调整。
主要发现
- 1年时GLP-1受体激动剂组106,858例中发生14例NAION(18.5/10万),DPP-4抑制剂组416,369例中发生53例(7.2/10万)。
- GLP-1受体激动剂较DPP-4抑制剂NAION风险升高:RR 2.56(95%CI 1.44-4.86),RD 11.3/10万。
- NAION风险在使用前6个月较高,随使用时间延长而减弱。
- 年龄<50岁、男性、曾吸烟及HbA1c下降≥1%的患者中NAION风险更高。
临床怎么用
- 对2型糖尿病患者启用GLP-1受体激动剂时,尤其年轻、男性、曾吸烟及HbA1c大幅下降者,应关注NAION相关视觉症状。
- NAION绝对风险增加幅度较小(RD 11.3/10万),临床决策仍需结合GLP-1受体激动剂的心血管和代谢获益综合评估。
局限性
- 为观察性队列模拟目标试验,不能完全排除残余混杂。
- NAION事件数较少,尤其GLP-1受体激动剂组仅14例,估计精度受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the effect of initiating glucagon-like peptide 1 receptor agonists (GLP-1 RAs) versus dipeptidyl peptidase 4 (DPP-4) inhibitors on incident nonarteritic anterior ischemic optic neuropathy (NAION) among adults with type 2 diabetes. RESEARCH DESIGN AND METHODS: This active-comparator, new-user cohort emulated a pragmatic target trial using the U.K. Clinical Practice Research Datalink. Patients aged ≥18 years with a physician diagnosis of type 2 diabetes who newly initiated a GLP-1 RA or a DPP-4 inhibitor were included. DPP-4 inhibitors were selected as the comparator because they may be used as second-line treatment, like GLP-1 RAs, and have no established association with NAION. We estimated risks, risk differences (RDs), and risk ratios (RRs) of incident NAION, adjusted using propensity-score fine-stratification weighting. RESULTS: At 1 year, there were 14 NAION events among 106,858 GLP-1 RA initiators (18.5 per 100,000) and 53 among 416,369 DPP-4 inhibitor initiators (7.2 per 100,000). GLP-1 RAs were associated with an increased risk of NAION compared with DPP-4 inhibitors (RR 2.56; 95% CI 1.44-4.86; RD 11.3 per 100,000). The risk of NAION was higher during the first 6 months of use, diminishing with longer duration of use, and was higher in patients aged <50 years, men, ever-smokers, and those with ≥1% hemoglobin A1c reduction. CONCLUSIONS: GLP-1 RAs were associated with an increased 1-year risk of NAION compared with DPP-4 inhibitors among adults with type 2 diabetes, particularly in younger patients, men, ever-smokers, and patients with a marked hemoglobin A1c reduction.
引用
- Noh Y, Yin H, Ben Ghezala I, et al. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes. Diabetes Care. 2026. PMID: 41701611. doi:10.2337/dc25-2577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。